TrialLancet (London, England)2023

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.

Hope S Rugo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.